These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1399 related articles for article (PubMed ID: 27903500)

  • 1. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
    Shin DS; Zaretsky JM; Escuin-Ordinas H; Garcia-Diaz A; Hu-Lieskovan S; Kalbasi A; Grasso CS; Hugo W; Sandoval S; Torrejon DY; Palaskas N; Rodriguez GA; Parisi G; Azhdam A; Chmielowski B; Cherry G; Seja E; Berent-Maoz B; Shintaku IP; Le DT; Pardoll DM; Diaz LA; Tumeh PC; Graeber TG; Lo RS; Comin-Anduix B; Ribas A
    Cancer Discov; 2017 Feb; 7(2):188-201. PubMed ID: 27903500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
    Zaretsky JM; Garcia-Diaz A; Shin DS; Escuin-Ordinas H; Hugo W; Hu-Lieskovan S; Torrejon DY; Abril-Rodriguez G; Sandoval S; Barthly L; Saco J; Homet Moreno B; Mezzadra R; Chmielowski B; Ruchalski K; Shintaku IP; Sanchez PJ; Puig-Saus C; Cherry G; Seja E; Kong X; Pang J; Berent-Maoz B; Comin-Anduix B; Graeber TG; Tumeh PC; Schumacher TN; Lo RS; Ribas A
    N Engl J Med; 2016 Sep; 375(9):819-29. PubMed ID: 27433843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
    Torrejon DY; Abril-Rodriguez G; Champhekar AS; Tsoi J; Campbell KM; Kalbasi A; Parisi G; Zaretsky JM; Garcia-Diaz A; Puig-Saus C; Cheung-Lau G; Wohlwender T; Krystofinski P; Vega-Crespo A; Lee CM; Mascaro P; Grasso CS; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Discov; 2020 Aug; 10(8):1140-1157. PubMed ID: 32467343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.
    Zhang C; Li D; Xiao B; Zhou C; Jiang W; Tang J; Li Y; Zhang R; Han K; Hou Z; Zhang L; Sui Q; Liao L; Pan Z; Zhang X; Ding P
    J Immunother; 2022 May; 45(4):187-193. PubMed ID: 35343934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.
    Chen L; Diao L; Yang Y; Yi X; Rodriguez BL; Li Y; Villalobos PA; Cascone T; Liu X; Tan L; Lorenzi PL; Huang A; Zhao Q; Peng D; Fradette JJ; Peng DH; Ungewiss C; Roybal J; Tong P; Oba J; Skoulidis F; Peng W; Carter BW; Gay CM; Fan Y; Class CA; Zhu J; Rodriguez-Canales J; Kawakami M; Byers LA; Woodman SE; Papadimitrakopoulou VA; Dmitrovsky E; Wang J; Ullrich SE; Wistuba II; Heymach JV; Qin FX; Gibbons DL
    Cancer Discov; 2018 Sep; 8(9):1156-1175. PubMed ID: 30012853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
    Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
    Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 8. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
    Sucker A; Zhao F; Pieper N; Heeke C; Maltaner R; Stadtler N; Real B; Bielefeld N; Howe S; Weide B; Gutzmer R; Utikal J; Loquai C; Gogas H; Klein-Hitpass L; Zeschnigk M; Westendorf AM; Trilling M; Horn S; Schilling B; Schadendorf D; Griewank KG; Paschen A
    Nat Commun; 2017 May; 8():15440. PubMed ID: 28561041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
    Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
    Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
    Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
    Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations.
    Ren Y; Zhang Y; Liu RZ; Fenstermacher DA; Wright KL; Teer JK; Wu J
    Sci Rep; 2013 Oct; 3():3042. PubMed ID: 24154688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
    Albacker LA; Wu J; Smith P; Warmuth M; Stephens PJ; Zhu P; Yu L; Chmielecki J
    PLoS One; 2017; 12(11):e0176181. PubMed ID: 29121062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
    Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
    Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
    Johnson DB; Frampton GM; Rioth MJ; Yusko E; Xu Y; Guo X; Ennis RC; Fabrizio D; Chalmers ZR; Greenbowe J; Ali SM; Balasubramanian S; Sun JX; He Y; Frederick DT; Puzanov I; Balko JM; Cates JM; Ross JS; Sanders C; Robins H; Shyr Y; Miller VA; Stephens PJ; Sullivan RJ; Sosman JA; Lovly CM
    Cancer Immunol Res; 2016 Nov; 4(11):959-967. PubMed ID: 27671167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.
    Hornakova T; Springuel L; Devreux J; Dusa A; Constantinescu SN; Knoops L; Renauld JC
    Haematologica; 2011 Jun; 96(6):845-53. PubMed ID: 21393331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of
    Gstalder C; Liu D; Miao D; Lutterbach B; DeVine AL; Lin C; Shettigar M; Pancholi P; Buchbinder EI; Carter SL; Manos MP; Rojas-Rudilla V; Brennick R; Gjini E; Chen PH; Lako A; Rodig S; Yoon CH; Freeman GJ; Barbie DA; Hodi FS; Miles W; Van Allen EM; Haq R
    Cancer Discov; 2020 Sep; 10(9):1296-1311. PubMed ID: 32371478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990
    [No Abstract]   [Full Text] [Related]  

  • 20. How Melanoma Resists PD-1 Blockade.
    Cancer Discov; 2016 Sep; 6(9):937-8. PubMed ID: 27486158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.